China’s Leading Diagnostic Reagent Manufacturer Colorcom Bio: Innovation-Driven Growth for Global Health
April 20, 2025 – Colorcom Bio, a top-tier global diagnostic reagent manufacturer, announced significant advancements in technological innovation, global collaboration, and social responsibility, reinforcing its leadership in the global diagnostics industry.
Colorcom Bio unveiled its multi-pathogen detection kit, leveraging proprietary nano-fluorescent labeling technology to achieve 50% higher sensitivity than conventional methods. The kit detects 12 pathogens—including SARS-CoV-2, influenza, and respiratory syncytial virus—within 15 minutes. It has obtained CE certification and is slated for release in Southeast Asian and African markets in Q2 2025 to bolster local public health infrastructure.
Colorcom Bio entered a strategic partnership with a leading European biotechnology firm to co-develop an AI-powered automated testing platform. Integrating Colorcom Bio’s reagent technology with advanced AI analytics, the platform enhances lab efficiency and reduces manual errors. The two parties will also establish a joint R&D center in Europe, focusing on rapid infectious disease diagnostics and early cancer screening technologies.
Colorcom Bio reaffirmed its commitment to social impact by donating portable testing devices and reagents worth over RMB 5 million to undeveloped regions in Western China. The initiative, coupled with free community health screenings, was highlighted in its 2025 Social Responsibility Report, aligning with its mission of “technology for the people.”
Colorcom Bio reaffirmed its commitment to social impact by donating portable testing devices and reagents worth over RMB 5 million to underserved regions in Western China. The initiative, coupled with free community health screenings, was highlighted in its 2025 Social Responsibility Report, aligning with its mission of “technology for the people.”
Post time: 2025-05-12 17:10:31